September 15, 2026 · Phase 2 readout
ORIC Phase 2 readout: a neutral outcome, -2.3%
On September 15, 2026, ORIC-114 — Oric Pharmaceuticals, Inc. (Solid Tumors) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved -2.3% in the window around the event. It had already run -13.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$12.65
1d before
$12.36
Event day
$12.54
1d after
$12.79
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -2.3%. Model confidence at the time: 200%.
See the full scored track recordPre-catalyst setup
-13.2%
30-day run-up
4949%
30-day volatility
1.5×
volume spike